Insulin LY2605541 tops glargine for glycemic control in T1DM

January 13, 2013
Insulin LY2605541 tops glargine for glycemic control in T1DM
For patients with type 1 diabetes, the novel, long-acting basal insulin LY2605541 yields greater improvement in glycemic control compared with insulin glargine, according to a study published online Nov. 27 in Diabetes Care.

(HealthDay)—For patients with type 1 diabetes, the novel, long-acting basal insulin LY2605541 yields greater improvement in glycemic control compared with insulin glargine, according to a study published online Nov. 27 in Diabetes Care.

Julio Rosenstock, M.D., of the Dallas Diabetes and Endocrine Center, and colleagues conducted a randomized, phase 2, open-label, crossover study involving 137 patients with type 1 diabetes who received once-daily (LY2605541 or glargine) plus mealtime insulin for eight weeks.

Compared with , the researchers found that LY2605541 met non-inferiority and superiority criteria and correlated with a significant reduction in the mean (least squares mean difference, −9.9 mg/dL). Significant improvements were also noted in fasting blood glucose variability and glycated hemoglobin with LY2605541 versus insulin glargine. There was a decrease in the mealtime insulin dose and in mean weight with LY2605541, and an increase in both with insulin glargine. The rate of nocturnal hypoglycemia was significantly lower with LY2605541, while the incidence of total hypoglycemia was significantly higher. LY2605541 was also associated with more gastrointestinal-related adverse events than insulin glargine (15 versus 4 percent).

"In conclusion, LY2605541 basal for patients with type 1 diabetes has the potential to improve glycemic control, reduce weight, glucose variability, and nocturnal hypoglycemia, and lower prandial insulin requirements," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Eli Lilly, which funded the study.

Explore further: Insulin glargine's main metabolic effect as metabolite M1

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Insulin glargine's main metabolic effect as metabolite M1

October 25, 2012
(HealthDay)—For patients with type 2 diabetes, following administration of a subcutaneous injection of a therapeutic dose of insulin glargine, glargine is minimally detectable in blood, and most of the plasma insulin concentration ...

Experimental insulin drug prevents low blood sugar

June 25, 2012
An experimental insulin drug prevented low blood sugar among diabetic patients more often than a popular drug on the market, a new study finds. The results will be presented at The Endocrine Society's 94th Annual Meeting ...

Study debunks belief insulin puts people with diabetes at risk of heart disease

June 11, 2012
Researchers at McMaster University have discovered that long-term insulin use does not harm people with diabetes or pre-diabetes or put them at risk of heart attacks, strokes or cancer.

The effect of insulin glargine and fish oil supplements on atherosclerosis progression

August 27, 2012
A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared ...

Automatic suspension of insulin delivery via insulin pumps reduces hypoglycemia

February 9, 2012
An automated on/off feature built into insulin pump systems can suspend insulin delivery when it detects low blood glucose levels (via continuous glucose monitoring), significantly reducing the severity and duration of hypoglycemia ...

Recommended for you

Diabetes can be tracked with our Google searches

July 26, 2017
The emergence of Type 2 Diabetes could be more effectively monitored using our Google searches—helping public health officials keep track of the disease and halt its spread—according to research by the University of Warwick.

Scientists discover a new way to treat type 2 diabetes

July 21, 2017
Medication currently being used to treat obesity is also proving to have significant health benefits for patients with type 2 diabetes. A new study published today in Molecular Metabolism explains how this therapeutic benefit ...

Alzheimer's drug cuts hallmark inflammation related to metabolic syndrome by 25 percent

July 20, 2017
An existing Alzheimer's medication slashes inflammation and insulin resistance in patients with metabolic syndrome, a potential therapeutic intervention for a highly dangerous condition affecting 30 percent of adults in the ...

Diabetes or its precursor affects 100 million Americans

July 19, 2017
Almost one-third of the US population—100 million people—either has diabetes or its precursor condition, known as pre-diabetes, said a government report Tuesday.

One virus may protect against type 1 diabetes, others may increase risk

July 11, 2017
Doctors can't predict who will develop type 1 diabetes, a chronic autoimmune disease in which the immune system destroys the cells needed to control blood-sugar levels, requiring daily insulin injections and continual monitoring.

Diabetes complications are a risk factor for repeat hospitalizations, study shows

July 7, 2017
For patients with diabetes, one reason for hospitalization and unplanned hospital readmission is severe dysglycemia (uncontrolled hyperglycemia - high blood sugar, or hypoglycemia - low blood sugar), says new research published ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.